Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 8/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142098 | 0.78 | AS3MT (0.45) | TSHRIKBKEGHSRL3MBTL1MAPT | |
| SCHEMBL21608058 | 0.74 | GHSR (0.49) | TSHRGHSRBRD4RAB9A | |
| SCHEMBL22778923 | 0.71 | PIK3CD (0.46) | TSHRIKBKEGHSRDHFR | |
| SCHEMBL5311581 | 0.69 | TSHR (1.00) | TSHRIDO1AGXT | |
| SCHEMBL27380 | 0.69 | TSHR (1.00) | TSHRIDO1AGXT | |
| Benzene SCHEMBL27997624 | 0.69 | TSHR (1.00) | TSHRIDO1AGXT | |
| SCHEMBL9007462 | 0.68 | TSHR (0.56) | TSHRL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL7575814 | 0.68 | TSHR (0.68) | TSHRL3MBTL1MAPTMAPK1TDP1 | |
| SCHEMBL23854651 | 0.68 | TSHR (0.50) | TSHRIKBKEGHSRIDO1DHFR | |
| SCHEMBL958531 | 0.68 | TSHR (0.50) | TSHRIKBKEGHSRL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | TSHR 4632/4885IKBKE 1896/4885GHSR 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.